Cardiogenic shock: Dopamine or norepinephrine? It's a question
Main Authors: | Ben He, Lingcong Kong, Junbo Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2017-01-01
|
Series: | Cardiology Plus |
Online Access: | http://www.cardiologyplus.org/article.asp?issn=2470-7511;year=2017;volume=2;issue=1;spage=1;epage=4;aulast=He |
Similar Items
-
Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock
by: Soo Jin Na, et al.
Published: (2022-01-01) -
Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock.
by: Soo Jin Na, et al.
Published: (2022-01-01) -
Norepinephrine use in cardiogenic shock patients is associated with increased 30 day mortality
by: Xin Lu, et al.
Published: (2022-06-01) -
Comparative study of dopamine and norepinephrine in the management of septic shock
by: Avinash Agrawal, et al.
Published: (2011-01-01) -
Norepinephrine was superior in death risk reducing and hemodynamics compared to dopamine in treatment of patients with septic shock
by: Lu Xudong, et al.
Published: (2021-02-01)